Drug Profile


Latest Information Update: 06 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Calgary
  • Developer Arch Biopartners
  • Class Anti-inflammatories; Antibacterials; Antineoplastics; Peptides
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer metastases; Sepsis

Most Recent Events

  • 01 Nov 2017 Preclinical trials in Cancer metastases in Canada (unspecified route)
  • 01 Nov 2017 Preclinical trials in Sepsis in Canada (unspecified route)
  • 01 Nov 2017 Arch Biopartners plans a pre-IND meeting with the US FDA in early 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top